Drug Profile
Research programme: respiratory disorder therapeutics - Pulmatrix
Alternative Names: Fluticasone/salmeterol dry powder - Pulmatrix; Levofloxacin dry powder - Pulmatrix; PUR 0400; PUR 0500; PUR 0600; PUR 0700; PUR 1000; PUR 113; PUR 1500; PUR 1700; Salmeterol/fluticasone dry powder - Pulmatrix; SD 101 - Pulmatrix; SD 102Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Pulmatrix
- Class Androstadienes; Anti-inflammatories; Biological proteins; Fluoroquinolones; Phenethylamines; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunomodulators; Lipocortin synthesis agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis-associated respiratory tract infections; Idiopathic pulmonary fibrosis; Influenza virus infections; Respiratory tract disorders; Respiratory tract infections
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Asthma in USA (Inhalation)
- 22 Feb 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
- 22 Feb 2023 Discontinued - Preclinical for Cystic fibrosis-associated respiratory tract infections (Prevention) in USA (Inhalation)